CSBR Sees Over 20% Revenue Growth, ORTX Plunges, SNOA Down 83% YTD

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Zomedica Pharmaceuticals Corp. (ZOM)

Zomedica is a development-stage veterinary diagnostic and pharmaceutical company.

Lost 27.67% to close Monday's (Nov.19) trading at $1.15.

News: No news

Recent event:

-- On November 13, the Company reported consolidated financial results for the third quarter ended September 30, 2018.

Net loss for the recent third quarter was $1.91 million or $0.02 per share compared to a net loss of $2.08 million or $0.02 per share in the year-ago quarter. The Company ended September 30, 2018, with cash and cash equivalents of $526,817.

2. Diversicare Healthcare Services Inc. (DVCR)

Diversicare is provider of post-acute care, offering a range of services from short term rehabilitation for individuals recovering from an injury or illness, to longer term care like providing memory care programs.

Lost 20.45% to close Monday's trading at $4.59.

News: No news

Recent event:

-- On Nov.1, the Company reported results for the third quarter ended September 30, 2018.

Net loss from continuing operations for the recent third quarter widened to $7.4 million or $1.15 per share from $0.6 million or $0.09 per share in the third quarter of 2017. Net patient revenues in the third quarter of 2018 declined to $141.43 million from $146.4 million in the year-earlier quarter.

3. Sonoma Pharmaceuticals Inc. (SNOA)

Lost 18.47% to close Monday's trading at $0.90.

News: No news

Recent events:

On November 17, the Company priced its public offering of units at $1.00 per unit. Each unit consists of one share of common stock, together with one half of one warrant to purchase one share of common stock.

The offering is expected to close on or about November 21, 2018, subject to customary closing conditions.

On Nov.8, the Company reported financial results for the second quarter FY 2019 ending September 30, 2018.

Net loss for the recent quarter narrowed to $2.82 million or $0.44 per share from $2.87 million or $0.67 per share in the comparable quarter last year. Total revenue was $4.9 million for the quarter ending September 30, 2018, was up 14% when compared to $4.3 million for the same period last year.

4. Champions Oncology Inc. (CSBR)

Champions Oncology is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs.

Lost 17.89% to close Monday's trading at $10.19.

News: No news

Recent event:

-- On September 13, 2018, the Company announced financial results for the first fiscal quarter ended July 31, 2018.

On a non GAAP basis, Champions Oncology posted a net income of $565 thousand or $0.05 per share in the recent first quarter compared to a net loss of $110 thousand or $0.01 per share in the year-ago quarter. Revenue increased 23.7% to $6.2 million in the first quarter of fiscal 2019 from $5.0 million in the first quarter of fiscal 2018.

Looking ahead, the Company expects annual revenue growth in excess of 20% for the full year ending April 30, 2019. The annual revenue was $20.2 million for the 12 months ended April 30, 2018.

5. Orchard Therapeutics plc (ORTX)

Orchard Therapeutics is a commercial-stage biopharmaceutical company dealing with innovative gene therapies for serious and life-threatening rare diseases.

Lost 14.44% to close Monday's trading at $16. The stock touched an all-time high of $19.24 in intraday trading.

News: No news

Recent event:

-- On October 31, 2018, the Company went public on the Nasdaq Global Select Market, offering its American Depositary Shares at a price of $14.00 per share.

The Company's marketed drug is Strimvelis, a personalised gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), also known as bubble boy syndrome that was approved in Europe in 2016.

Pipeline:

OTL-101 for adenosine deaminase severe combined immunodeficiency; OTL-103 for Wiskott Aldrich syndrome, and OTL-200 for metachromatic leukodystrophy, all three of which are under phase III registrational studies.

OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for Beta-thalassemia, both of which are under clinical proof of concept studies.